Studies from Sungkyunkwan University Update Current Data on B-Cell Lymphoma (Car T Cells Vs Bispecific Antibody As Third- or Later-line Large B-cell Lymphoma Therapy: a Meta-analysis).

The article reports on a meta-analysis comparing the efficacy and safety of CAR T-cell therapy and bispecific antibodies for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Topics include the higher complete response (CR) rates and 1-year progression-free survival rates of CAR T-cell therapy compared to bispecific antibodies, as well as differences in severe adverse event rates between the two treatments.